Letter to the editor on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study".
作者信息
Wu Meng-Che, Chang Hui-Chin, Jhang Yi-Sheng, Gau Shuo-Yan
机构信息
Division of Pediatric Gastroenterology, Children's Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan.
Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
出版信息
Clin Mol Hepatol. 2025 Jan;31(1):e13-e14. doi: 10.3350/cmh.2024.0682. Epub 2024 Sep 2.
Abstract
摘要
相似文献
1
Letter to the editor on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study".致编辑的信：关于“阿特珠单抗/贝伐单抗治疗失败后索拉非尼与仑伐替尼治疗晚期肝细胞癌的真实世界研究”
Clin Mol Hepatol. 2025 Jan;31(1):e13-e14. doi: 10.3350/cmh.2024.0682. Epub 2024 Sep 2.
2
Correspondence to letter to the editor on "Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study".致编辑的信，内容为关于“阿替利珠单抗/贝伐单抗治疗失败后索拉非尼与乐伐替尼治疗晚期肝细胞癌的真实世界研究”。
Clin Mol Hepatol. 2025 Jan;31(1):e98-e100. doi: 10.3350/cmh.2024.0916. Epub 2024 Oct 21.
3
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study.索拉非尼对比乐伐替尼治疗阿特珠单抗/贝伐珠单抗治疗后进展的肝细胞癌：一项真实世界研究。
Clin Mol Hepatol. 2024 Jul;30(3):345-359. doi: 10.3350/cmh.2023.0553. Epub 2024 Mar 12.
4
Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database.接受阿替利珠单抗联合贝伐单抗与索拉非尼或乐伐替尼作为一线治疗的不可切除肝细胞癌真实世界患者的总生存期：来自美国退伍军人健康管理局数据库的研究结果
Cancers (Basel). 2024 Oct 17;16(20):3508. doi: 10.3390/cancers16203508.
5
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.阿替利珠单抗联合贝伐珠单抗对比仑伐替尼或索拉非尼用于非病毒性不可切除肝细胞癌：一项国际倾向性评分匹配分析。
ESMO Open. 2022 Dec;7(6):100591. doi: 10.1016/j.esmoop.2022.100591. Epub 2022 Oct 6.
6
Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study".阿替利珠单抗和贝伐单抗治疗肝细胞癌：如何对无反应者进行挽救治疗？：关于“阿替利珠单抗/贝伐单抗治疗失败后索拉非尼与仑伐替尼治疗晚期肝细胞癌的真实世界研究”的社论
Clin Mol Hepatol. 2024 Oct;30(4):682-688. doi: 10.3350/cmh.2024.0324. Epub 2024 May 7.
7
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.贝伐珠单抗或仑伐替尼联合阿替利珠单抗一线治疗后序贯治疗肝细胞癌患者。
Eur J Cancer. 2023 Aug;189:112933. doi: 10.1016/j.ejca.2023.05.021. Epub 2023 Jun 1.
8
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.乐伐替尼对比索拉非尼用于经阿替利珠单抗联合贝伐单抗治疗后进展的肝细胞癌患者的二线治疗：一项回顾性真实世界研究
Oncology. 2025;103(6):456-468. doi: 10.1159/000541018. Epub 2024 Oct 11.
9
Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis.一线阿替利珠单抗联合贝伐单抗治疗失败后，索拉非尼或仑伐替尼用于晚期肝细胞癌的疗效和安全性：一项系统评价和荟萃分析
Cancers (Basel). 2024 Aug 10;16(16):2813. doi: 10.3390/cancers16162813.
10
Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.一线系统治疗晚期肝细胞癌的选择：一项随机对照试验的网络荟萃分析。
World J Gastroenterol. 2021 May 21;27(19):2415-2433. doi: 10.3748/wjg.v27.i19.2415.
引用本文的文献
1
Correspondence to letter to the editor on "Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study".致编辑的信，内容为关于“阿替利珠单抗/贝伐单抗治疗失败后索拉非尼与乐伐替尼治疗晚期肝细胞癌的真实世界研究”。
Clin Mol Hepatol. 2025 Jan;31(1):e98-e100. doi: 10.3350/cmh.2024.0916. Epub 2024 Oct 21.
本文引用的文献
1
New-Onset Hidradenitis Suppurativa in Psoriasis Patients: A Multi-Center, Retrospective Cohort Study.银屑病患者新发化脓性汗腺炎：一项多中心回顾性队列研究
Life (Basel). 2024 Jun 6;14(6):730. doi: 10.3390/life14060730.
2
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study.索拉非尼对比乐伐替尼治疗阿特珠单抗/贝伐珠单抗治疗后进展的肝细胞癌：一项真实世界研究。
Clin Mol Hepatol. 2024 Jul;30(3):345-359. doi: 10.3350/cmh.2023.0553. Epub 2024 Mar 12.
3
Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma.肝细胞癌免疫治疗生物标志物的前沿进展
Front Oncol. 2023 Jan 16;12:1091088. doi: 10.3389/fonc.2022.1091088. eCollection 2022.
4
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
Zotero 插件